Title: Prevalence and Determinants of Hypertension Among People Living with HIV on Antiretroviral Therapy: A Cross-Sectional Study at Mwananyamala Hospital, Tanzania.

Authors:

Meshack Morice,

University of Dar es Salaam, Dar es Salaam, Tanzania,

Email: meshackmorice@gmail.com

Co-authors:

Jacqueline Mgumia,

University of Dar es Salaam,

P.O. Box 35091,

Dar es Salaam, Tanzania.

Phone: +255 754 242 323.

Email: jhm11@albion.edu.

Corresponding Author:

Meshack Morice,

University of Dar es Salaam,

P.O. Box 35091,

Dar es Salaam, Tanzania.

Phone: +255 764 910 402.

Email: meshackmorice@gmail.com .

Keywords: HIV, Hypertension, Antiretroviral Therapy, Prevalence, Tanzania

Word Count: 2,588 (main text, excluding Title Page, Abstract, Tables, Acknowledgments, References)

Figures: 1 (+1 supplementary)

Tables: 4 (+2 supplementary)

References: 30

ABSTRACT

Introduction: Hypertension is an emerging concern among people living with HIV (PLHIV) on antiretroviral therapy (ART), with limited data from Tanzania. This study aimed to determine the prevalence and determinants of hypertension among PLHIV on ART.

Methods: A cross-sectional study was conducted at Mwananyamala Regional Referral Hospital, Tanzania, in July 2024. We enrolled 296 PLHIV on ART for >6 months using simple random sampling. Data on sociodemographic characteristics, HIV-related factors, and hypertension knowledge were collected through structured questionnaires. Blood pressure and body mass index (BMI) were measured. Bivariate and multivariate logistic regression analyses assessed associations between HIV-related factors and hypertension (defined as ≥140/90 mmHg or use of antihypertensive medication).

Results: The prevalence of hypertension was 32.8% (97/296). Longer duration of HIV diagnosis (1–5 years: adjusted odds ratio [aOR] 5.119, 95% CI 1.772–14.787, p=0.003; 6–10 years: aOR 3.738, 95% CI 1.568–8.910, p=0.003) and higher CD4 counts (≥500 cells/mm³: aOR 11.505, 95% CI 1.287–102.853, p=0.029; 350–499 cells/mm³: aOR 12.173, 95% CI 1.389–106.670, p=0.024) were associated with increased hypertension risk. Shorter ART duration (<1 year: aOR 0.122, 95% CI 0.016–0.935, p=0.043) reduced risk. Traditional risk factors (age >35 years, overweight/obesity, family history of hypertension, physical inactivity) also increased hypertension risk. Knowledge of hypertension was moderate (53.85%), with 21.6% demonstrating good knowledge.

Conclusions: Hypertension is prevalent among PLHIV on ART in Tanzania, driven by HIV-related and traditional risk factors. Integrated screening and education within HIV care are critical.

Keywords: HIV, Hypertension, Antiretroviral Therapy

KEY MESSAGES

- **What is already known on this topic:** Hypertension prevalence among PLHIV on ART in sub-Saharan Africa varies widely (6%-53%), with conflicting evidence on HIV-related risk factors and limited data on knowledge levels.

- **What this study adds:** This study reports a 32.8% hypertension prevalence among PLHIV on ART in Tanzania, identifying longer HIV duration, higher CD4 counts, and traditional risk factors as key determinants, while highlighting moderate hypertension knowledge.

- **How this study might affect research, practice, or policy:** These findings underscore the need for routine hypertension screening in HIV care, targeted health

education, and longitudinal studies to establish causality between HIV/ART and hypertension.

INTRODUCTION

Hypertension, defined as blood pressure ≥140 mmHg systolic or ≥90 mmHg diastolic or use of antihypertensive medication, is a growing public health concern globally, affecting a quarter of individuals living with HIV in the previous decade and contributing to cardiovascular diseases (CVD), stroke, heart failure, eye problems (blindness) and other health-related issues [1-5]. Among people living with HIV (PLHIV), the advent of antiretroviral therapy (ART) has transformed HIV into a manageable chronic condition, significantly improving survival rates [6,7]. However, this prolonged survival has shifted morbidity patterns from opportunistic infections to non-communicable diseases, notably hypertension [8]. Studies suggest PLHIV on ART face a higher hypertension risk than the general population, potentially due to HIV-induced inflammation, ART side effects, and traditional risk factors such as alcohol drinking and cigarrete smoking [9].

Global prevalence of hypertension among PLHIV on ART was reported to be 23.6% [1], with the prevalencein Sub-saharan Africa ranging from 6% to 53%, compared to ART-naïve individuals (2–41%) [10-11]. In Tanzania, where HIV prevalence declined from 7% in 2003 to 4.5% in 2021 among adults aged 15–49 [12,13], hypertension among PLHIV on ART remains understudied. A Tanzanian study reported a 25.2% prevalence among long-term ART users (≥5 years) versus 6.9% in ART-naïve patients, suggesting a potential ART-related effect [14]. However, evidence on HIV-related factors (i.e., CD4 count, ART duration,HIV staging and HIV diagnosis duration) and hypertension risk is inconsistent, with some studies finding no association [15,16], while others report strong links [14,17].

Knowledge gaps about hypertension among PLHIV further complicate prevention efforts. Limited awareness of risk factors and complications hinders behavioral interventions[18-20], yet few studies in Tanzania have assessed this. Addressing these gaps is critical, as hypertension is a primary contributor to CVD, a leading cause of morbidity in PLHIV [2,3]. This study aimed to determine the prevalence and determinants of hypertension among PLHIV on ART at Mwananyamala Hospital, Tanzania, examining HIV-related factors and hypertension knowledge to inform targeted interventions.

MATERIALS AND METHODS

Study Design and Setting

This quantitative, prospective cross-sectional study was conducted from July 2 to August 3, 2024 at Mwananyamala Regional Referral Hospital (MRRH), a major referral facility in Kinondoni District, Dar es Salaam, Tanzania. Established in 2004, MRRH's Care and Treatment Clinic (CTC) serves approximately 26,000 PLHIV annually, with 50–100 daily visits, making it an ideal site for studying hypertension in this population [21].

Participants

This study enrolled 296 PLHIV aged ≥18 years, on ART for >6 months, attending the CTC during the study period. Pregnant women and those on contraceptive pills were excluded due to potential blood pressure confounding effects. Eligibility was confirmed using CTC records.

Variables

The dependent variable was hypertension. Independent variables included HIV-related factors (duration of HIV diagnosis, CD4 count, WHO stage, ART duration) and knowledge level. Confounding variables were traditional risk factors (age, gender, smoking, alcohol use, BMI, family history, physical activity). There were no missing data for any variables analyzed, including sociodemographic characteristics, HIV-related factors, and knowledge of hypertension, as all 296 participants provided complete responses and measurements.

Data Collection

Data were collected through structured questionnaires administered in Swahili during one-on-one interviews in a private room post-clinic visits. Sociodemographic data (age, gender, education, occupation, smoking, alcohol use, physical activity, family history of hypertension) and hypertension knowledge were self-reported. HIV-related factors (duration of HIV diagnosis, CD4 count, WHO HIV clinical stage, ART duration) were extracted from CTC records.

Bias

To minimize selection bias, this study used simple random sampling from daily CTC patient lists, ensuring all eligible participants had an equal chance of selection. To reduce measurement bias, blood pressure was measured by two trained nurses using calibrated

sphygmomanometers following American Heart Association guidelines [22], with two readings averaged from separate occasions to enhance accuracy. Potential recall bias in self-reported data (e.g., smoking, alcohol use, physical activity) was mitigated by structured, pretested questionnaires with clear, simple questions to improve recall accuracy. Confounding was addressed in the multivariate logistic regression analysis by adjusting for traditional risk factors (age, gender, BMI, family history, physical activity, smoking, alcohol use).

Sample Size and Sampling

Sample size was calculated using the formula:

$N= [Z^2 *P(1-P)]/E^2$

where Z=1.96 Z = 1.96 Z=1.96 (95% confidence interval), P=0.26 (prevalence from a Tanzanian study [19], and E=0.05 (margin of error), yielding an initial N=296.

To account for a 10% non-response rate, the adjusted sample size was calculated as:

$N_{adjusted}= N/(1-\text{non-response rate})= 296/(1-0.10)=329$

Thus, 329 participants were targeted to ensure 296 completed the study. Simple random sampling was employed: daily CTC patient lists were generated, each patient assigned a random number, and 329 were selected using a computer-generated random number generator. Of these, 296 participated.

Patient and Public Involvement

Patients participated in data collection through interviews, shaping the knowledge assessment. Results will be disseminated through CTC education sessions.

Blood Pressure Measurement

Blood pressure was measured by two registered nurses using a calibrated sphygmomanometer, following American Heart Association guidelines [22]. Participants rested for 5 minutes, seated with feet flat, arm supported at heart level. Two readings, 1–2 minutes apart, were averaged from two separate occasions. Hypertension was defined as ≥140/90 mmHg or current antihypertensive use.

Anthropometric Measurement

Height and weight were measured using a Weight and Height Scale, and BMI was calculated (kg/m²) using a mobile application. BMI categories were: underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), obese (≥30).

Knowledge Assessment

A 10-question scale assessed hypertension knowledge (normal blood pressure, risk factors, complications), scored as a percentage (0–100%). Categories were: low (0–30%), moderate (40–70%), good (80–100%).

Data Validity and Reliability

A pretest with 10 PLHIV refined the questionnaire for clarity and relevance. Reliability was ensured through a Cronbach's Alpha of ≥0.70 (SPSS 25), standardized protocols, and regular equipment calibration. Data entry was double-checked.

Data Analysis

Data were analyzed using SPSS 25. Prevalence was calculated using descriptive statistics and cross-tabulations. Bivariate logistic regression assessed crude odds ratios (COR) for HIV-related factors and hypertension, followed by multivariate logistic regression for adjusted odds ratios (aOR), controlling for confounders. Knowledge was evaluated thtough frequencies and composite scores. Significance was set at p<0.05.

Ethical Considerations

Ethical clearance was obtained from the University of Dar es Salaam Vice Chancellor, with permissions from regional authorities and MRRH. Written informed consent was secured, ensuring confidentiality through coded questionnaires.

RESULTS

Participant Flow

Of the approximately 1,845 PLHIV on ART for >6 months attending the CTC during from July 2 to August 3, 2024, 1,695 were potentially eligible after excluding an estimated 150 pregnant women or those on contraceptive pills. From these, 329 were randomly selected using a computer-generated random number generator from daily patient lists to account for a 10% non-response rate. Of the 329 approached, 33 declined participation due to time constraints or unwillingness to consent, resulting in 296 participants who consented and completed the study (Figure 1).

Descriptive Characteristics

Of 296 participants, 66.6% (197) were female, and 34.8% (103) were aged 45–54 years. Most had primary education (66.9%, 198) and were business owners (48.6%, 144). Lifestyle factors included 7.8% (23) smokers, 23.6% (70) alcohol users, and 44.9% (133) physically inactive. Family history of hypertension was reported by 21.3% (63), and 58.8% (174) were overweight/obese (Supplementary Table 1).

Prevalence of Hypertension

Hypertension prevalence was 32.8% (97/296). Among hypertensives, 56.3% (36/64) were ≥55 years, and 59.1% (13/22) had no formal education. Unemployment (41.8%, 41/98), physical inactivity (39.1%, 52/133), family history (42.9%, 27/63), and obesity (45.8%, 33/72) were associated with higher prevalence(Table 1).

Table 1: Sociodemographic characteristics in hypertensive and non-hypertensive

	Hypertensive n (%)	Non hypertensive n (%)	Total
Age (years)			
18-24	2(16.7)	10(83.3)	12
25-34	6(18.8)	26(81.3)	32
35-44	21(24.7)	64(75.3)	85
45-54	32(31.1)	71(68.9)	103
≥55	36(56.3)	28(43.8)	64
Gender			
Female	64(32.5)	133(67.5)	197
Male	33(33.3)	66(66.7)	99
Level of education			
No formal education	13(59.1)	9(40.9)	22
Primary school	60(30.3)	138(69.7)	198

	Hypertensive n (%)	Non hypertensive n (%)	Total
Secondary school	18(31.0)	40(69.0)	58
High school	0(0.0)	4(100.0)	4
College degree	6(42.9)	8(57.1)	14
Occupation			
Business owner	38(26.4)	106(73.6)	144
Employed	15(32.6)	31(67.4)	46
Farmer	3(37.5)	5(62.5)	8
Unemployed	41(41.8)	57(58.2)	98
Cigarette smokers	3(13.0)	20(87.0)	23
Alcohol drinkers	25(35.7)	45(64.3)	70
Physical activity			
Not very active	52(39.1)	81(60.9)	133
Moderately active	38(28.6)	95(71.4)	133
Very active	7(23.3)	23(76.7)	30
Family history of HTN	27(42.9)	36(57.1)	63
BMI (kg/m$^{2)}$			
Underweight (<18.5)	5(33.3)	10(66.7)	15
Normal weight (18.5-24.9)	25(23.4)	82(76.6)	107
Overweight (25-29.9)	34(33.3)	68(66.7)	102
Obese ($\geq$ 30)	33(45.8)	39(54.2)	72
TOTAL	**97(32.8)**	**199(67.2)**	**296**

HIV-related factors showed higher prevalence with longer HIV duration (6–10 years: 38.2%, 34/89), advanced WHO stages (Stage 3: 35.6%, 63/177), CD4 200–349 cells/mm³ (44.4%, 20/45), and ART 1–5 years (36.5%, 19/52) (Table 2).

Table 2: HIV-related factors associated with HTN

	Hypertensive n (%)	Non hypertensive n (%)	Total
Duration with HIV diagnosis (years)			
<1	1(5.9)	16(94.1)	17
1-5	19(36.5)	33(63.5)	52
6-10	34(38.2)	55(61.8)	89
>10	43(31.2)	95(68.8)	138
HIV clinical staging			
Stage 1	13(26.0)	37(74.0)	50
Stage 2	12(28.6)	30(71.4)	42
Stage 3	63(35.6)	114(64.4)	177
Stage 4	9(33.3)	18(66.7)	27
Current CD4 cell count (cells/mm3)			
<200	1(4.8)	20(95.2)	21
200-349	20(44.4)	25(55.6)	45

350-499	32(34.0)	62(66.0)	94
≥500	44(32.4)	92(67.6)	136
Duration of ART use (years)			
<1	1(5.9)	16(94.1)	17
1-5	19(36.5)	33(63.5)	52
>5	77(33.9)	150(66.1)	227
TOTAL	**97(32.8)**	**199(67.2)**	**296**

Association Between HIV-Related Factors and Hypertension

Bivariate Analysis

Longer HIV duration (1–5 years: COR 0.297, 95% CI 0.121–0.730, p=0.008; 6–10 years: COR 0.359, 95% CI 0.172–0.750, p=0.006) and higher CD4 counts (≥500 cells/mm³: COR 0.079, 95% CI 0.009–0.692, p=0.022) reduced hypertension risk compared to reference categories. ART <1 year increased risk (COR 8.213, 95% CI 1.069–63.095, p=0.043). WHO stage showed no association (p>0.05) (Table 3).

Table 3: Bivariate analysis of HIV-related factors associated with HTN

	n	Crude Odds ratio (95% C.I)	P-value
Duration with HIV diagnosis (years)			
<1	17	1.494(0.149-14.962)	0.732
1-5	52	0.297(0.121-0.730)	0.008
6-10	89	0.359(0.172-0.750)	0.006
>10	138	1	
HIV clinical staging			
Stage 1	50	2.197(0.620-7.788)	0.223
Stage 2	42	1.858(0.504-6.847)	0.352
Stage 3	177	1.331(0.463-3.823)	0.596
Stage 4	27	1	
Current CD4 cell count (cells/mm3)			
≥500	136	0.079(0.009-0.692)	0.022
350-499	94	0.066(0.008-0.578)	0.014
200-349	45	0.057(0.006-0.532)	0.012
<200	21	1	
Duration of ART use (years)			
<1	17	8.213 (1.069-63.095)	0.043
1-5	52	0.892(0.476-1.670)	0.720
>5	227	1	

Multivariate Analysis

Adjusting for confounders, longer HIV duration increased hypertension risk (1–5 years: aOR 5.119, 95% CI 1.772–14.787, p=0.003; 6–10 years: aOR 3.738, 95% CI 1.568–8.910, p=0.003. Higher CD4 counts were strongly associated (≥500 cells/mm³: aOR 11.505, 95% CI 1.287–102.853, p=0.029; 350–499 cells/mm³: aOR 12.173, 95% CI 1.389–106.670, p=0.024). ART <1 year reduced risk (aOR 0.122, 95% CI 0.016–0.935, p=0.043). WHO stage remained non-significant (p>0.05) (Table 4).

Table 4: Multivariate analysis of HIV-related factors associated with HTN

	n	Adjusted Odds ratio (95% C.I)	P value
Duration with HIV diagnosis (years)			
<1	17	1.485(0.146-15.082)	0.738
1-5	52	5.119(1.772-14.787)	0.003
6-10	89	3.738(1.568-8.910)	0.003
>10	138	1	
HIV clinical staging			
Stage 1	50	0.386(0.091-1.637)	0.197
Stage 2	42	0.290(0.060-1.410)	0.125
Stage 3	177	0.888(0.274-2.883)	0.843
Stage 4	27	1	
Current CD4 cell count (cells/mm3)			
≥500	136	11.505(1.287-102.853)	0.029
350-499	94	12.173(1.389-106.670)	0.024
200-349	45	8.480(0.830-86.585)	0.071
<200	21	1	
Duration of ART use(years)			
<1	17	0.122 (0.016-0.935)	0.043
1-5	52	1.122(0.599-2.101)	0.720
>5	227	1	

Knowledge of Hypertension

Knowledge was moderate (mean 53.85%), with 26.4% (78) scoring low (0–30%), 52% (154) moderate (40–70%), and 21.6% (64) good (80–100%) (Supplementary Figure 1). Only 10.8% (32) knew normal blood pressure, while awareness of risk factors like exercise (90.9%, 269) and weight gain (73.0%, 216) was higher than smoking (22.6%, 67). Complications awareness ranged from 46.3% (kidney problems) to 68.6% (heart problems) (Supplementary Table 2).

DISCUSSION

Prevalence of Hypertension

This study found a 32.8% hypertension prevalence among PLHIV on ART, higher than the global average (23.6%) [1] but within Sub-Saharan African ranges (6–53%) [10,11]. Compared to Tanzanian studies (25.2% in long-term ART users [14]), our findings suggest a significant burden, aligning with Ghana (36.7%) [23] and South Africa (53%) [11], yet exceeding lower estimates from Burundi (17.4%) [24] and Kenya (16%) [16]. Traditional risk factors—older age (>35 years), overweight/obesity, physical inactivity, and family history— mirrored prior studies [23,25], reinforcing their role in PLHIV. HIV-related factors, including longer ART duration and advanced WHO stages, also increased prevalence, consistent with previous studies [19,23] .

HIV-Related Factors and Hypertension

Longer HIV duration (1–5 and 6–10 years) significantly increased hypertension risk, supporting previous studies [24,25]. Chronic inflammation and immune dysfunction may explain this [26,27]. However, a study done in Ghana [23] found no association, possibly due to methodological differences. Higher CD4 counts (≥350 cells/mm³) were strongly linked to hypertension, aligning with previous literature [23], but contrasting with studies reporting lower risk [11,19,28]. Immune reconstitution or lifestyle changes post-ART may contribute [29]. Shorter ART duration (<1 year) reduced risk, consistent with previous studies [17,25], suggesting prolonged ART exposure elevates hypertension risk, possibly through drug toxicity or lipodystrophy [17]. No association with WHO stage contrasts with previous literatures [19,30], potentially due to smaller sample size or ART's mitigating effects on disease progression.

Knowledge of Hypertension

Moderate knowledge (53.85%) with significant gaps (26.4% low knowledge levels) aligns with existing literaure [15,20], highlighting a need for education. Low awareness of normal blood pressure (10.8%) and smoking (22.6%) as risk factors contrasts with higher awareness of exercise (90.9%), indicating inconsistent understanding. This study's structured assessment improves on prior vague methodologies in evaluating knowledge on hypertension [19], offering a clearer picture of knowledge deficits.

GENERALISABILITY

Conducted at a single urban referral hospital (Mwananyamala Regional Referral Hospital) in Dar es Salaam, Tanzania, the findings may not fully represent rural or less-resourced settings where access to antiretroviral therapy (ART) and healthcare infrastructure differs significantly. The study's sample of 296 participants, while statistically justified, reflects a specific population of PLHIV on ART for over six months, excluding ART-naïve individuals and pregnant women, which restricts applicability to these groups. However, the use of standardized measurements and a diverse participant profile (e.g., varying age, education, and occupation) enhances relevance to similar urban HIV care settings in Tanzania and potentially other East African countries with comparable healthcare systems, suggesting moderate external validity within this context.

STRENGTHS AND LIMITATIONS

This study's strengths include a standardized measurements, and comprehensive HIV-related factor analysis. However, excluding ART-naïve patients limits comparisons, and the cross-sectional design precludes causality. Unmeasured comorbidities (e.g., diabetes) and potential pre-HIV hypertension may confound results. The moderate sample size (296) may reduce power for some associations (e.g., WHO stage).

IMPLICATIONS FOR PRACTICE AND POLICY

The 32.8% prevalence and identified risk factors necessitate integrating routine blood pressure screening into HIV care, as recommended by WHO [2]. Education programs targeting knowledge gaps (e.g., normal blood pressure, smoking) could empower PLHIV to mitigate risks. Policymakers should prioritize hypertension management protocols within CTCs, emphasizing lifestyle modifications.

FUTURE RESEARCH

Longitudinal studies are needed to establish causality between HIV/ART and hypertension, including ART-naïve controls. Expanding variables (e.g., comorbidities) and determining hypertension incidence post-HIV diagnosis would enhance understanding. Larger samples could clarify inconsistent findings (e.g., WHO stage).

ACKNOWLEDGMENTS

I thank Dr. Jacqueline Mgumia for supervision, Mwananyamala Regional Referral Hospital (MRRH) staff for support, and participants for their time.

FUNDING STATEMENT

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

COMPETING INTERESTS STATEMENT

The authors declares no competing interests.

CONTRIBUTOR STATEMENT

Meshack Morice conceived the study, collected and analysed data, and wrote the manuscript. Jacqueline Mgumia supervised the study design and provided critical revisions to the manuscript

REFERENCES

1. Bigna JJ, Ndoadoumgue AL, Nansseu JR, Tochie JN, Nyaga UF, Nkeck JR, et al. Global burden of hypertension among people living with HIV in the era of increased life expectancy: a systematic review and meta-analysis. *J Hypertens*. 2020;38(9):1659-68.

2. WHO. Cardiovascular diseases (CVDs). Geneva: World Health Organization; 2021. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

3. Fragkou PC, Moschopoulos CD, Dimopoulou D, Triantafyllidi H, Birmpa D, Benas D, et al. Cardiovascular disease and risk assessment in people living with HIV: current practices and novel perspectives. *Hellenic J Cardiol*. 2023;71:42-54. https://doi.org/10.1016/j.hjc.2022.12.013

4. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. *Circulation*. 2023;147(1):83-100.

5. WHO. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023. https://reliefweb.int/report/world/global-report-hypertension-race-against-silent-killer

6. Epps PV, Kalayjian RC. Human Immunodeficiency Virus and aging in the era of effective antiretroviral therapy. *Infect Dis Clin North Am*. 2017;31(4):791-810.

7. Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. *Circulation*. 2018;138(11):1100-12.

8. Bigna JJ, Noubiap JJ. Global burden of hypertension in people living with HIV. *BMC Med*. 2021;19(1):112.

9. Carter M. A quarter of people living with HIV have hypertension. aidsmap.com. 2020. https://www.aidsmap.com/news/jun-2020/quarter-people-living-hiv-have-hypertension

10. Masenga SK, Hamooya BM, Nzala S, Kwenda G, Heimburger DC, Mutale W, et al. Patho-immune mechanisms of hypertension in HIV: a systematic and thematic review. *Curr Hypertens Rep*. 2019;21(7):56.

11. Tsuro U, Oladimeji KE, Pulido-Estrada GA, Apalata TR. Risk factors attributable to hypertension among HIV-infected patients on antiretroviral therapy in selected rural districts of the Eastern Cape Province, South Africa. *Int J Environ Res Public Health*. 2022;19(18):11196.

12. UNAIDS. Country progress report - United Republic of Tanzania, Global AIDS Monitoring. Geneva: UNAIDS; 2020. https://www.unaids.org/sites/default/files/country/documents/TZA_2020_countryreport.pdf

13. USAID. Tanzania HIV/AIDS fact sheet. Washington, DC: USAID; 2023. https://www.usaid.gov/tanzania/fact-sheet/tanzania-hivaids-fact-sheet

14. Kato I, Tumaini B, Pallangyo K. Prevalence of non-communicable diseases among individuals with HIV infection by antiretroviral therapy status in Dar es Salaam, Tanzania. *PLoS One*. 2020;15(7):e0235542.

15. Derick KI, Khan Z. Prevalence, awareness, treatment, control of hypertension, and availability of hypertension services for patients living with Human Immunodeficiency Virus (HIV) in Sub-Saharan Africa (SSA): a systematic review and meta-analysis. *Cureus*. 2023;15(4):e37422.

16. Mogaka JN, Sharma M, Temu T, Masyuko S, Kinuthia J, Osoti A, et al. Prevalence and factors associated with hypertension among adults with and without HIV in Western Kenya. *PLoS One*. 2022;17(1):e0262400.

17. Pangmekeh PJ, Awolu MM, Gustave S, Gladys T, Cumber SN. Association between highly active antiretroviral therapy (HAART) and hypertension in persons living with HIV/AIDS at the Bamenda regional hospital, Cameroon. *Pan Afr Med J*. 2019;33:87.

18. Kagaruki GB, Mayige MT, Ngadaya ES, Kilale AM, Kahwa A, Shao AF, et al. Knowledge and perception on type 2 diabetes and hypertension among HIV clients utilizing care and treatment services: a cross-sectional study from Mbeya and Dar es Salaam regions in Tanzania. *BMC Public Health*. 2018;18(1):928.

19. Trifirò S, Cavallin F, Mangi S, Mhaluka L, Maffoni S, Taddei S, et al. Hypertension in people living with HIV on combined antiretroviral therapy in rural Tanzania. *Afr Health Sci*. 2023;23(1):129-36.

20. Biraguma J, Mutimura E, Frantz JM. Knowledge about modifiable risk factors for non-communicable diseases adults living with HIV in Rwanda. *Afr Health Sci*. 2019;19(4):3181-9.

21. Mwabenga BK. Effectiveness of HIV/AIDS social support coping skill to PLWHA in Kinondoni Municipality, Dar es Salaam: a case study of Mwananyamala Hospital. [place unknown]: [publisher unknown]; 2019.

22. American Heart Association. Standards for measuring blood pressure. Dallas, TX: American Heart Association; 2018. https://www.heart.org/en/health-topics/high-blood-pressure/understanding-blood-pressure-readings

23. Nartey ET, Tetteh RA, Anto F, Sarfo B, Kudzi W, Adanu RM. Hypertension and associated factors among patients attending HIV clinic at Korle-Bu Teaching Hospital. *Ghana Med J*. 2023;57(1):19-27.

24. Harimenshi D, Niyongabo T, Preux PM, Aboyans V, Desormais I. Hypertension and associated factors in HIV-infected patients receiving antiretroviral treatment in Burundi: a cross-sectional study. *Sci Rep*. 2022;12(1):20529.

25. Melo ES, Antonini M, Costa CRB, Sorensen W, Gir E, Reis RK. Evaluation of cardiovascular risk factors in people living with HIV in São Paulo, Brazil. *J Infect Dev Ctries*. 2020;14(1):89-96.

26. Chelvanambi S. Mechanisms of HIV-Nef induced endothelial cell stress: implications of HIV-Nef protein persistence in aviremic HIV patients. Ann Arbor, MI: ProQuest; 2019. https://www.proquest.com/docview/2305768926

27. Avagimyan A, Pogosova N, Kakturskiy L, Sheibani M, Urazova O, Trofimenko A, et al. HIV-related atherosclerosis: state-of-the-art review. *Curr Probl Cardiol*. 2023;48(9):101783.

28. Uwanyirigira D, Biracyaza E, Uzabakiriho I, Omolo J, Hakizayezu F, Nzayirambaho M. Prevalence and factors associated with hypertension among HIV positive patients on antiretroviral therapy: a hospital-based cross-sectional study in Rwanda. *Vasc Health Risk Manag*. 2023;19:857-70.

29. Molopi D. The vascular and endothelial effects of HIV, antiretroviral therapy and rooibos - functional effects and mechanism. Stellenbosch: Stellenbosch University; 2022. http://hdl.handle.net/10019.1/126003

30. Kamiński M, Prymas P, Konobrodzka A, Filberek P, Sibrecht G, Sierocki W, et al. Blood pressure in relation to the World Health Organization AIDS clinical staging among adults living in rural Kenya. *HIV AIDS Rev*. 2020;19(2):93-8.

FIGURE LEGENDS:

Figure 1: Flow diagram of participant selection**.**

SUPPLEMENTARY FILES:

1. **Supplementary Figure 1:** Histogram showing the distribution of hypertension knowledge scores (%).
2. **Supplementary Table 1:** Descriptive characteristics of the study population
3. **Supplemenatry Table 2:** Hypertension knowledge assessment parameters in PLHIV on ART.

Figure 1: Flow diagram of participant selection